Dr Reddy's inks deal with US firm for marketing ibuprofen

New Delhi, Jul 8 (UNI) Dr Reddy's Laboratories Ltd, a leading pharmaceutical firm, today said it has signed an agreement with the US-based Albemarle Corporation for marketing active pharmaceutical ingredient 'ibuprofen' to its global clients.

Under the agreement, Dr Reddy's, a non-exclusive distributor of Albemarle's bulk 'ibuprofen' active pharmaceutical ingredients (API), will market, sell and distribute the API to its global clients.

In addition, Albemarle will also supply Dr Reddy's a substantial quantity of its ibuprofen API requirements for use in the company's generic ibuprofen tablets.

Albemarle is a global manufacturer of the anti-inflammatory agent ibuprofen and other APIs.

UNI SR SBA UCS1939